Deutsche Bank AG boosted its holdings in Puma Biotechnology Inc (NASDAQ:PBYI) by 340.1% in the 4th quarter, Holdings Channel reports. The firm owned 497,035 shares of the biopharmaceutical company’s stock after purchasing an additional 384,099 shares during the period. Deutsche Bank AG’s holdings in Puma Biotechnology were worth $10,113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Puma Biotechnology by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 2,819,118 shares of the biopharmaceutical company’s stock valued at $129,257,000 after purchasing an additional 85,319 shares during the last quarter. Vanguard Group Inc raised its position in Puma Biotechnology by 3.1% in the 3rd quarter. Vanguard Group Inc now owns 2,819,118 shares of the biopharmaceutical company’s stock valued at $129,257,000 after purchasing an additional 85,319 shares during the last quarter. BlackRock Inc. raised its position in Puma Biotechnology by 1.6% in the 4th quarter. BlackRock Inc. now owns 2,665,886 shares of the biopharmaceutical company’s stock valued at $54,250,000 after purchasing an additional 41,785 shares during the last quarter. Great Point Partners LLC purchased a new stake in Puma Biotechnology in the 4th quarter valued at $28,077,000. Finally, Millennium Management LLC raised its position in Puma Biotechnology by 406.7% in the 4th quarter. Millennium Management LLC now owns 1,332,696 shares of the biopharmaceutical company’s stock valued at $27,120,000 after purchasing an additional 1,069,706 shares during the last quarter. Hedge funds and other institutional investors own 91.92% of the company’s stock.

Shares of Puma Biotechnology stock opened at $32.86 on Thursday. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -10.99 and a beta of 0.70. The company has a quick ratio of 2.99, a current ratio of 3.02 and a debt-to-equity ratio of 4.43. Puma Biotechnology Inc has a one year low of $17.60 and a one year high of $68.90.

Several analysts recently commented on PBYI shares. Leerink Swann started coverage on shares of Puma Biotechnology in a research report on Thursday, January 17th. They issued a “market perform” rating and a $21.00 price target for the company. BidaskClub upgraded shares of Puma Biotechnology from a “strong sell” rating to a “sell” rating in a research report on Friday, January 25th. Guggenheim downgraded shares of Puma Biotechnology from a “buy” rating to a “neutral” rating in a research report on Thursday, January 3rd. JPMorgan Chase & Co. reiterated a “sell” rating and issued a $27.00 price target on shares of Puma Biotechnology in a research report on Sunday, March 3rd. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $57.00 price target on shares of Puma Biotechnology in a research report on Thursday, February 28th. Six equities research analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $51.91.

In other Puma Biotechnology news, insider Alan H. Auerbach sold 8,825 shares of the company’s stock in a transaction on Tuesday, January 22nd. The shares were sold at an average price of $24.74, for a total transaction of $218,330.50. Following the completion of the transaction, the insider now owns 4,165,812 shares in the company, valued at approximately $103,062,188.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 10,245 shares of company stock valued at $268,052. 21.50% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2019/04/18/deutsche-bank-ag-grows-position-in-puma-biotechnology-inc-pbyi.html.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).

Further Reading: Cost of Capital Explained

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NASDAQ:PBYI).

Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.